Explore our materials

International Workshop on HIV & Hepatitis Co-infection 2017

Pharmacologist's perspective | David Back, PhD

Charles Boucher

MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Virologist's perspective | Charles Boucher, MD, PhD

Kosh Agarwal

International Workshop on HIV & Hepatitis Co-infection 2017

Special considerations before / during / after DAA therapy | Kosh Agarwal, MD

International Workshop on HIV & Hepatitis Co-infection 2017

HBV cure: what is coming in 5 – 10 years? | Patrick Kennedy, MD

Jürgen Rockstroh

International Workshop on HIV & Hepatitis Co-infection 2017

EASL highlights 2017 | Jürgen Rockstroh, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Management of end-stage liver disease in HIV patients | Ana Morbey, MD

Vincent Soriano

MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

News on hepatitis delta and HIV infections | Vincent Soriano, MD, PhD

Kenneth Sherman

MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Hepatitis E in HIV | Kenneth Sherman, MD, PhD

RSeC

Rui Sarmento e Castro

MD, PhD, MPH

International Workshop on HIV & Hepatitis Co-infection 2017

Management of HCV in intravenous drug users: special considerations | Rui Sarmento e Castro, MD, PhD

International Workshop on HBV Cure 2018

Session 1 Panel discussion

Thomas Berg

International Workshop on HBV Cure 2018

Stopping Nucleos(t)ide Analogues: When is it beneficial, when is it dangerous? | Thomas Berg, MD

Adam Gehring

PhD